Rakovina Therapeutics pays part of its debt with shares due to cash constraints.

Rakovina Therapeutics, a company developing cancer treatments, announced that some debentureholders will receive shares instead of cash for part of their $91,000 interest payment due on November 28, 2024. Approximately $20,500 will be settled with common shares, and the rest in cash. The number of shares issued will be determined based on the discounted market price and TSX Venture Exchange policies.

3 months ago
3 Articles

Further Reading